New for 2022! Integrated Sessions

The 2022 meeting will feature twelve (12) integrated sessions, which will be a led by an expert invited speaker, and combine lectures and supporting oral abstract presentations.

Saturday, June 11 | 1:30-3:00 pm PDT
Integrated Session 1: Total Body PET systems: Latest Developments
Invited Speaker: Austin Pantel, MD

Presentations include:

  • Performance evaluation of the PennPET Explorer with expanded axial coverage
  • Activity optimization and evaluation of semi-quantitative performance for the Biograph Vision Quadra PET/CT
  • Kernel SIME: simultaneous estimation of blood input function using a kernel method and its evaluation with total-body PET
  • Real-time Motion Tracking for Total-body Molecular Imaging
  • Attenuation correction of Total Body PET using syntetic CT derived from the emission data


Saturday, June 11 | 3:15-4:45 pm PDT
Integrated Session 2: COVID Session
Invited Speaker: Ali Gholamrezanezhad, MD

Presentations include:

  • A prospective study to investigate the implementation of semiquantitative inflammatory load in post-COVID-19 lung disease (PCLD) to strategize therapy
  • Total-Body Imaging of CD8+ T Cells in Patients Recovering from COVID-19 – A Pilot Study Using the uEXPLORER Total-Body PET
  • Vaccine-associated hypermetabolic lymphadenopathy on 18F-FDG PET/CT: Experience from a single center in Mexico
  • Multi-organ metabolic changes in COVID-19 recovery measured with total-body dynamic 18F-FDG PET
  • Molecular imaging PET-CT in oncologic patients with unsuspected asymptomatic infection with SARS-CoV-2. The Spanish experience (Delta and Omicron variants)


Sunday, June 12 | 12:30-2:00 PM PDT
Integrated Session 3: Unique Radionuclides and Their Applications
Invited Speaker: Buck Rodgers, PhD

Presentations include:

  • 177Lu and 225Ac dose escalation using a novel class of PSMA radioligands with low salivary gland and kidney retention in a preclinical model of human prostate cancer
  • Development of [55,58mCo]Co-NOTA-NTS20.3 as a versatile theranostic nuclear medicine
  • Manufacturing of [211At]NaAt for the first‑in‑human clinical trial of targeted alpha therapy for differentiated thyroid cancer at Osaka University Hospital
  • A primary activity standard for Pb-212 in equilibrium with its progeny
  • Preclinical Evaluation of 43Sc-FAPI PET for Detection of Pancreatic Ductal Adenocarcinoma


Sunday, June 12 | 3:00-4:30pm PDT
Integrated Session 4: Oncology Basic/Translational Integrated Session
Invited Speaker: Xiaoyuan (Shawn) Chen, PhD, FSNMMI

Presentations include:

  • CD8 targeted PET imaging of M002 oncolytic virus and checkpoint blockade therapy in preclinical models of glioblastoma
  • Prospectively planned and Independent Validation of aPROMISE in a Phase III CONDOR Study for Rapid Lesion Detection and Standardized Quantitative Evaluation for 18F-DCFPyL (PSMA) Imaging in Prostate Cancer.
  • Getting a GRIP on antitumor immunity with granzyme targeted PET
  • Artificial Intelligence-generated PET images for PSMA-PET/CT studies: Quantitative and Qualitative Assessment
  • Monitoring Therapeutic Response to FAP CAR T Cells using [18F]AlF-FAPI-74 PET


Sunday, June 12 | 4:45-6:15 pm PDT
Integrated Session 5: FAPI
Invited Speaker: Frederik L. Giesel, MD

Presentations include:

  • Usefulness of 68Ga-FAPI-04 and 18F-FDG PET/CT for identifying the primary and metastatic lesions in patients with gastrointestinal cancer: a comparative study
  • Comparison of 68Ga-FAPI and 18F-FDG uptake in patients with gastric signet-ring cell carcinoma: A multicenter retrospective study
  • Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi versus [18F]F-FDG PET/CT in radioiodine refractory differentiated thyroid cancer patients
  • Head to head comparison of 68Ga-FAPI-46 PET/CT and 18-FDG PET/CT in breast carcinoma staging: a clinical trial update from Azerbaijan
  • 68Ga-FAPI and 18F-FDG PET/CT in Evaluation of Primary and Metastatic Lesions in Late-stage Hepatocellular Carcinoma
  • 68Ga-FAPI PET/CT improves tumor detection and staging in patients with pancreatic cancer and comparison with 18F-FDG PET/CT


Monday, June 13 | 10:00-11:30 am PDT
Integrated Session 6: Advances in Tau imaging
Invited Speaker: TBA

Presentations include:

  • Quantitative measurement of cerebral perfusion from early phase [18F]MK6240 tau-PET imaging
  • A multicenter [18F]PI-2620 PET study for in vivo staging of tau pathology in progressive supranuclear palsy
  • Head-to-head comparison of Relative Cerebral Blood Flow derived from dynamic [18F]florbetapir and [18F]flortaucipir PET studies in subjects with Subjective Cognitive Decline
  • World Trade Center First Responders Exhibit Potentially Unique Tau Neuropathology: A Pilot PET/MRI Study
  • Optimization of imaging time for 18F-AV45 PET using SUVR in cognitive impairment with or without CAA by total‑body dynamic PET/CT
  • Methodological approaches to improve Tau PET SUVR quantification in 4-repeat tau phenotypes: A multicenter study


Monday, June 13 | 1:00-2:30 pm PDT
Integrated Session 7: Novel developments in prostate and liver imaging and therapy
Invited Speaker: Steven Rowe, MD

Presentations include:

  • Effects of replacing Glu in the PSMA-targeting Lys-urea-Glu pharmacophore of [68Ga]Ga-HTK03041 with a close derivative on the uptake of tumor xenograft, kidneys and salivary glands
  • A novel stereospecific PSMA-targeting pharmacophore with reduced kidney and salivary gland accumulation in a murine model of human prostate cancer
  • In the search of new chelator to improve prostate cancer radiotheranostic, the study of 64Cu/177Lu-CT-PCTA-PSMA
  • In vivo PET imaging of liver cancer stem cells using 64Cu-NOTA-1B50-1-F(ab`)2
  • GPC3-targeted ImmunoPET Imaging of Hepatocellular Carcinomas


Monday, June 13 | 4:00-5:30 pm PDT
Integrated Session 8: novel neuroreceptor radiotracers and brain/whole body applications
Invited Speaker: Richard Carson, PhD

Presentations include:

  • An investigation of the “brain-GI” relationships in Parkinson’s disease by imaging dopamine transporter in dynamic 11C-CFT total-body PET/CT
  • Whole-body PET imaging in humans shows that 11C-PS13 is selective for cyclooxygenase-1 and can measure the in vivo potency of nonsteroidal anti-inflammatory drugs
  • First-in-human evaluation of 18F-PF-06445974, a PET radioligand that preferentially labels phosphodiesterase-4B
  • Chemistry, Radiochemistry and Preliminary Biological Evaluations of the First Brain-penetrant GPR119-based Radiotracer in Rodents and Non-human primates
  • First-in-human in vivo imaging and quantification of monoacylglycerol lipase in the brain: A PET study with 18F-T-401
  • First-in-human brain imaging with [18F]3F4AP, a PET tracer developed for imaging demyelination


Tuesday, June 14 | 8:00-9:30 am PDT
Integrated Session 9: Cardiac Amyloidosis: Advances in Imaging and clinical applications
Invited Speaker: Mehran Sadeghi, MD

Presentations include:

  • Feasibility of fibroblast activation positron emission tomography in amyloid light-chain amyloidosis
  • Final Results of the First-In-Human Study of the Amyloid-Reactive Peptide 124I-p5+14, (Iodine[124I] Evuzamitide; AT-01) For the Detection of Systemic Amyloidosis
  • A final diagnosis of cardiac amyloidosis is rare in patients with equivocal Tc-99m PYP: A single-center experience.
  • 99mTc-PYP SPECT/CT and 11C-PIB PET/CT for cardiac involvement of transthyretin and light-chain amyloidosis


Tuesday, June 14 | 10:00-11:30 am PDT
Integrated Session 10: PET/CT for imaging of infection and inflammation: Novel radiotracers and methods
Invited Speaker: Gad Abikhzer MDCM, FRCPC, ABNM

Presentations include:

  • 5h-delayed [18F]-FDG total-body PET/CT in diagnosis of Takayasu’s arteritis
  • Imaging tumor-targeting bacteria using 18F-FDS PET
  • PET Imaging of Neutrophil Trafficking Fungal Infection
  • The value of 18F-FDG PET/CT in detection of osteomyelitis in patients with stage IV pressure ulcers
  • The combination of 18F-FDG PET metabolic parameters and clinical parameters can effectively distinguish polymyalgia rheumatic and rheumatoid arthritis


Tuesday, June 14 | 1:00-2:30 pm PDT
Integrated Session 11: AI for Nuclear Medicine and Molecular Imaging
Invited Speaker: Irene Buvat, PhD

Presentations include:

  • Federated Learning on 18F-FDG PET/CT Uptake Classification in Lung Cancer, Lymphoma and Head and Neck Cancer
  • Comparison of handcrafted radiomics and 3D-CNN models to diagnose striatal dopamine deficiency in Parkinson’s Disease based on (18)F-FDOPA PET images
  • Cross-site PET Image Harmonization by Using Unsupervised Deep Generative Adversarial Network for Improving Quantitative Indices Reproducibility
  • A Patlak-regularized deep learning inter-frame motion correction framework for whole-body dynamic PET
  • A graph neural network model for the prediction of longitudinal tau aggregation


Tuesday, June 14 | 3:00-4:30 pm PDT
Integrated Session 12: VISION trial and PSMA-therapy
Invited Speaker: Phillip Kuo, MD

Presentations include:

  • Multi-cycle dosimetry of [177Lu]Lu-PSMA-617 for the treatment of metastatic castration-resistant prostate cancer: results from the VISION trial sub-study
  • Reader agreement of [68Ga]Ga-PSMA-11 PET/CT scan interpretation to determine patient eligibility for [177Lu]Lu-PSMA-617 radioligand therapy: a VISION sub-study
  • Prognostic value of end-of-treatment 68Ga-PSMA-11 PET/CT in patients treated with 177Lu-PSMA radioligand therapy: a retrospective, single-center analysis
  • Predictive value of extra-prostatic disease detection by pre-operative PSMA-PET for biochemical recurrence free survival in patients with Radical Prostatectomy: follow-up analysis of a Multicenter Prospective Phase 3 Imaging Trial.
  • Body size and renal function are predictors of healthy tissue dosimetry in PSMA